MorphoSys AG (MOR) PT Set at €85.00 by Berenberg Bank
MorphoSys AG (ETR:MOR) received a €85.00 ($100.00) price target from stock analysts at Berenberg Bank in a research note issued to investors on Thursday. The firm presently has a “buy” rating on the stock.
Several other research firms also recently commented on MOR. Independent Research GmbH set a €84.00 ($98.82) price objective on MorphoSys AG and gave the company a “buy” rating in a report on Wednesday, October 4th. Deutsche Bank AG set a €90.00 ($105.88) price objective on MorphoSys AG and gave the company a “buy” rating in a report on Monday, August 7th. Goldman Sachs Group Inc set a €55.00 ($64.71) price objective on MorphoSys AG and gave the company a “neutral” rating in a report on Friday, August 4th. Oddo Bhf set a €81.00 ($95.29) price objective on MorphoSys AG and gave the company a “buy” rating in a report on Monday, September 25th. Finally, Commerzbank Ag set a €76.00 ($89.41) price objective on MorphoSys AG and gave the company a “buy” rating in a report on Wednesday, September 27th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of €79.00 ($92.94).
Shares of MorphoSys AG (MOR) opened at 73.974 on Thursday. The firm’s market capitalization is €2.14 billion. The firm has a 50-day moving average of €69.48 and a 200-day moving average of €62.21. MorphoSys AG has a 1-year low of €37.50 and a 1-year high of €75.45.
WARNING: This piece was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/21/morphosys-ag-mor-pt-set-at-85-00-by-berenberg-bank.html.
About MorphoSys AG
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Stock Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related stocks with our FREE daily email newsletter.